Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Blood (2023) 142 (Supplement 1): 5933.

https://doi.org/10.1182/blood-2023-179609

Published: 2023

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2023-181886

Published: 2023

Journal Articles

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali S. Advani, Daniel J. DeAngelo, Tibor J. Kovacsovics, Anand Jillella, Dale Bixby, Moshe Y. Levy, Megan M. O’Meara, Phoenix A. Ho, Jenna Voellinger, Anthony S. Stein

Blood (2018) 132 (11): 1125–1133.

https://doi.org/10.1182/blood-2018-03-841171

Published: 2018

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

Elie Traer, MD, Nathalie Javidi-Sharifi, Jacqueline Martinez, MS, Isabel English, Jennifer Dunlap, MD, Anupriya Agarwal, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker, MD

Blood (2016) 128 (22): 1080.

https://doi.org/10.1182/blood.V128.22.1080.1080

Published: 2016

Journal Articles

CX-01, a Low Anticoagulant Heparin, May Enhance Count Recovery and Treatment Efficacy in Acute Myeloid Leukemia

Tibor J. Kovacsovics, MD, Alice S. Mims, MD MSCR, Mohamed E Salama, MD, Jeremy M Pantin, MD, Ken M Kosak, B.S., Narayanam Rao, PhD, Peter Ahorukomeye, Martha Glenn, MD, Michael W. Deininger, MD PhD, Kenneth M Boucher, PhD, Linda M Bavisotto, MD, Gerardo Gutierrez-Sanchez, PhD, Thomas P Kennedy, MD MPH, Stephen Garrett Marcus, MD, Paul J Shami, MD

Blood (2016) 128 (22): 5220.

https://doi.org/10.1182/blood.V128.22.5220.5220

Published: 2016

Journal Articles

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Dale L. Bixby, MD PhD, Anthony S. Stein, MD, Amir T. Fathi, MD, Tibor J. Kovacsovics, MD, Moshe Y Levy, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Roland B. Walter, MD PhD MS, Eytan M. Stein, MD, Stefan Faderl, MD, Daniel J. DeAngelo, MD PhD, Phoenix Ho, MD, Megan M. O'Meara, MD, Jenna L Voellinger, PhD, Anjali Advani, MD

Blood (2016) 128 (22): 590.

https://doi.org/10.1182/blood.V128.22.590.590

Published: 2016

Journal Articles

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Amir T. Fathi, MD, Harry P Erba, MD PhD, Jeffrey E Lancet, MD, Eytan M Stein, Roland B. Walter, MD PhD MS, Daniel J. DeAngelo, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Anjali S. Advani, MD, Dale Bixby, MD PhD, Tibor J. Kovacsovics, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, Anthony S. Stein, MD

Blood (2015) 126 (23): 454.

https://doi.org/10.1182/blood.V126.23.454.454

Published: 2015

Journal Articles

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Anthony S. Stein, MD, Roland B. Walter, MD PhD MS, Harry P Erba, MD PhD, Amir T. Fathi, MD, Anjali S. Advani, MD, Jeffrey E Lancet, MD, Farhad Ravandi, MD, Tibor J. Kovacsovics, MD, Daniel J. DeAngelo, MD PhD, Dale Bixby, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Megan M. O'Meara, MD, Baiteng Zhao, PhD, Eytan M Stein

Blood (2015) 126 (23): 324.

https://doi.org/10.1182/blood.V126.23.324.324

Published: 2015

Journal Articles

Preliminary Evidence That ODSH (2-O, 3-O Desulfated Heparin) Is Safe and Enhances Count Recovery in Patients Treated with Intensive Therapy for Acute Myeloid Leukemia – Results of a Pilot Study

Tibor J. Kovacsovics, MD, Alice Mims, MD, Mohamed E Salama, MD, Jeremy M Pantin, Michael W. Deininger, Thomas P Kennedy, MD, Linda M Bavisotto, MD, Kenneth M Boucher, PhD, Stephen G Marcus, MD, Paul J Shami, MD

Blood (2014) 124 (21): 5297.

https://doi.org/10.1182/blood.V124.21.5297.5297

Published: 2014

Journal Articles

Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Eytan M. Stein, Anthony Stein, Roland B. Walter, MD PhD MS, Amir T. Fathi, MD, Jeffrey E. Lancet, MD, Tibor J. Kovacsovics, MD, Anjali S. Advani, MD, Daniel J DeAngelo, Megan M. O'Meara, MD, Baiteng Zhao, PhD, Dana A. Kennedy, PharmD, BCOP, Harry P. Erba, MD PhD

Blood (2014) 124 (21): 623.

https://doi.org/10.1182/blood.V124.21.623.623

Published: 2014

Journal Articles

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Jeffrey E. Lancet, Jorge E. Cortes, Donna E. Hogge, Martin S. Tallman, Tibor J. Kovacsovics, Lloyd E. Damon, Rami Komrokji, Scott R. Solomon, Jonathan E. Kolitz, Maureen Cooper, Andrew M. Yeager, Arthur C. Louie, Eric J. Feldman

Blood (2014) 123 (21): 3239–3246.

https://doi.org/10.1182/blood-2013-12-540971

Published: 2014

Includes: Supplemental data

Journal Articles

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

Elie Traer, MD, PhD, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer B Dunlap, MD, Isabel English, Jacqueline Martinez, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker

Blood (2013) 122 (21): 2541.

https://doi.org/10.1182/blood.V122.21.2541.2541

Published: 2013

Journal Articles

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Janice Gabrilove, MD, Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2061.

https://doi.org/10.1182/blood.V114.22.2061.2061

Published: 2009

Journal Articles

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Harry P Erba, Stefan Faderl, MD, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2083.

https://doi.org/10.1182/blood.V114.22.2083.2083

Published: 2009

Journal Articles

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Elizabeth Anderson, Elly Barry, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4155.

https://doi.org/10.1182/blood.V114.22.4155.4155

Published: 2009

Journal Articles

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

David F. Claxton, M.D., Thomas J Myers, MD, FACP, Harry P Erba, Stefan Faderl, MD, M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Clay R Warnock, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4162.

https://doi.org/10.1182/blood.V114.22.4162.4162

Published: 2009

Journal Articles

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

Eneida R. Nemecek, MD, Mohamed L. Sorror, MD, MS, Kristine C. Doney, MD, Bart Lee Scott, MD, Tibor J. Kovacsovics, MD, Richard Thomas Maziarz, MD, Ann E Woolfrey, MD, Jean Sanders, MD, Paul V. O’Donnell, Katherine Guthrie, PhD, H. Joachim Deeg, MD

Blood (2008) 112 (11): 2994.

https://doi.org/10.1182/blood.V112.11.2994.2994

Published: 2008

Journal Articles

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Harry Paul Erba, MD, PhD, Hagop Kantarjian, David F. Claxton, MD, M. Arellano, Roger M Lyons, MD, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Rekha Abichandani, MD, Stefan Faderl, MD

Blood (2008) 112 (11): 558.

https://doi.org/10.1182/blood.V112.11.558.558

Published: 2008

NARROW

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

CX-01, a Low Anticoagulant Heparin, May Enhance Count Recovery and Treatment Efficacy in Acute Myeloid Leukemia

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Preliminary Evidence That ODSH (2-O, 3-O Desulfated Heparin) Is Safe and Enhances Count Recovery in Patients Treated with Intensive Therapy for Acute Myeloid Leukemia – Results of a Pilot Study

Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only